Journal
VACCINE
Volume 34, Issue 45, Pages 5449-5456Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.08.055
Keywords
Pandemic influenza vaccine; Vietnam; IVAC; Clinical trial
Categories
Funding
- US Department of Health
- Human Services/BARDA [6 IDSEP130018-01-06]
Ask authors/readers for more resources
We tested an inactivated egg-grown whole virus influenza A/H5N1 vaccine candidate developed by the Institute of Vaccines and Medical Biologicals (IVAC), a state-run vaccine manufacturer in Vietnam, in a Phase 1, placebo controlled, double blinded, randomized trial. The vaccine was adjuvanted with aluminum hydroxide. The trial enrolled 75 subjects who were randomized to receive two injections of one of the following: low-dose of vaccine (7.5 mcg HA), high-dose of vaccine (15 mcg HA), or placebo. The vaccine candidate was well tolerated with minimal local reactogenicity consisting of mild, short-lived injection site pain and/or tenderness. No systemic reactogenicity was observed other than transient low-grade fever in about 13% of the subjects and no unsolicited adverse events were attributable to product administration. Immune responses were assessed at baseline and after the first and second dose by hemagglutination inhibition (HAI) and microneutralization (MN) assays, with 72% of the high-dose and 68% of the low-dose vaccine recipients presenting a >= 4-fold response in the HAI assay and 72% of the high-dose and 61% of the low-dose vaccine recipients exhibiting a >= 4-fold response in the MN assay. These promising results support further development. (C) 2016 Elsevier Ltd. This is an open access article under the CC BY license.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available